Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Day One Biopharmaceuticals (DAWN) Income from Continuing Operations (2023 - 2025)

Historic Income from Continuing Operations for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Q3 2025 value amounting to -$19.7 million.

  • Day One Biopharmaceuticals' Income from Continuing Operations fell 15494.42% to -$19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.7 million, marking a year-over-year increase of 2158.68%. This contributed to the annual value of -$204.7 million for FY2024, which is 838.43% down from last year.
  • According to the latest figures from Q3 2025, Day One Biopharmaceuticals' Income from Continuing Operations is -$19.7 million, which was down 15494.42% from -$30.3 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Income from Continuing Operations ranged from a high of $35.8 million in Q3 2024 and a low of -$112.4 million during Q2 2024
  • For the 3-year period, Day One Biopharmaceuticals' Income from Continuing Operations averaged around -$43.7 million, with its median value being -$46.0 million (2023).
  • In the last 5 years, Day One Biopharmaceuticals' Income from Continuing Operations skyrocketed by 17766.49% in 2024 and then crashed by 15494.42% in 2025.
  • Day One Biopharmaceuticals' Income from Continuing Operations (Quarter) stood at -$54.5 million in 2023, then dropped by 20.61% to -$65.7 million in 2024, then surged by 70.04% to -$19.7 million in 2025.
  • Its Income from Continuing Operations stands at -$19.7 million for Q3 2025, versus -$30.3 million for Q2 2025 and -$36.0 million for Q1 2025.